The role of a positron- and high-energy gamma photon probe in intraoperative localization of recurrent melanoma

被引:36
作者
Franc, BL
Mari, C
Johnson, D
Leong, SP
机构
[1] Univ Calif San Francisco, Dept Radiol, Nucl Med Program, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA
[4] Stanford Univ, Dept Surg, Stanford, CA 94305 USA
关键词
positron emission; radioguided surgery; melanoma; positron probe;
D O I
10.1097/01.rlu.0000186856.86505.96
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 [临床医学]; 100207 [影像医学与核医学]; 1009 [特种医学];
摘要
Purpose: This preliminary study retrospectively evaluated the ability of intraoperative localization of recurrent melanoma using F-18 fluorodeoxyglucose (FDG) and a probe sensitive to both high-energy gamma rays and positrons to enable complete tumor resection and improved patient outcome. Materials and Methods: Three hours before surgery for resection of recurrent melanoma, 5 patients (mean age, 52 22 years) with a history of local surgery, radiation therapy, and/or large habitus received 14.6 +/- 3.2 mCi of F-18 FDG. Intraoperative tumor localization was performed with a radiation probe (PET-Probe; IntraMedical Imaging LLC, Los Angeles, CA). Intraoperative tumor tissue activities, background tissue activities, pathology results, and patient follow up (clinical/imaging) were recorded. Results: Eight of the 19 surgical specimens were identified by the probe as having increased FDG uptake when compared with the surrounding tissues before resection. All 8 specimens contained melanoma. Of the 11 specimens that were not identified using the probe, one contained melanoma, yielding a sensitivity of 89% (8 of 9) and a specificity of 100% (10 of 10). In 3 of the 5 cases, the probe allowed the identification of nonvisualized and nonpalpable tumor foci that were later confirmed pathologic. At an average follow up of 210 days (range, 30-515 days), 2 of 5 patients had no evidence of recurrent melanoma by clinical or radiographic evaluations. Conclusion: In the setting of recurrent melanoma, there appear to be potential benefits to intraoperative detection with FDG and a positron-detecting probe, particularly in cases with challenging or altered anatomy.
引用
收藏
页码:787 / 791
页数:5
相关论文
共 10 条
[1]
Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma [J].
Acland, KM ;
Healy, C ;
Calonje, E ;
O'Doherty, M ;
Nunan, T ;
Page, C ;
Higgins, E ;
Russell-Jones, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2674-2678
[2]
Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma [J].
Eigtved, A ;
Andersson, AP ;
Dahlstrom, K ;
Rabol, A ;
Jensen, M ;
Holm, S ;
Sorensen, SS ;
Drzewiecki, KT ;
Hojgaard, L ;
Friberg, L .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (01) :70-75
[3]
Advances in FDG PET probes in surgical oncology [J].
Essner, R ;
Daghighian, F ;
Giuliano, AE .
CANCER JOURNAL, 2002, 8 (02) :100-108
[4]
Application of an [18F] fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy [J].
Essner, R ;
Hsueh, EC ;
Haigh, PI ;
Glass, EC ;
Huynh, Y ;
Daghighian, F .
JOURNAL OF SURGICAL RESEARCH, 2001, 96 (01) :120-126
[5]
Effectiveness of positron emission tomography for the detection of melanoma metastases [J].
Holder, WD ;
White, RL ;
Zuger, JH ;
Easton, EJ ;
Greene, FL .
ANNALS OF SURGERY, 1998, 227 (05) :764-771
[6]
Mijnhout GS, 2001, CANCER-AM CANCER SOC, V91, P1530, DOI 10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.3.CO
[7]
2-R
[8]
Tyler DS, 2000, CANCER, V89, P1019, DOI 10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO
[9]
2-0
[10]
FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume [J].
Wagner, JD ;
Schauwecker, DS ;
Davidson, D ;
Wenck, S ;
Jung, SH ;
Hutchins, G .
JOURNAL OF SURGICAL ONCOLOGY, 2001, 77 (04) :237-242